Pfizer in the news

Pfizer is currently the top gainer on the BSE; opening lower at Rs.4081, the stock rose to an intraday high at Rs.4448.35, up almost 9%. The stock is closer to its 52- low of Rs.4012.65 rather than the high of Rs.6452.85.

The stock is in the limelight after the company announced that its Board has approved a proposal to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals.

This is for marketing and sale of two brands of the company, viz., Ativan and Pacitane.

The agreement is for a period of 5 years for Indian region. Mylan has a good presence in Central Nervous System therapy area with skilled resources for engagement with super specialists namely Neurologist and Psychiatrist. Th e company said that this arrangement with Mylan will enhance distribution and in clinic presence of the products.

.